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Transcatheter Aortic Valve Replacement with a New Self-expanding
Percutaneous Heart Valve and Motorized Delivery System
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Jonathon Leipsic1, Stefan Toggweiler1, Melanie Freeman1, Alex Willson1,
John Webb1
1St. Paul’s Hospital - University of British Columbia, Vancouver, Canada,
2Asklepios Klinik St. Georg - University of Hamburg, Hamburg, Germany
Background: Refining transcatheter aortic valve replacement with newly designed
bioprosthesis and delivery systems is anticipated to reduce the risk of complications and
enhance ease of prosthesis implantation. We report the first-in-human experience and
short- and mid-term clinical outcomes with a new self-expanding transcatheter heart valve
and motorized delivery system.
Methods: The CENTERA valve (Edwards Lifesciences Inc., CA, USA) was implanted
in 15 patients with symptomatic severe aortic stenosis via percutaneous femoral or axillary
arterial access. Patients underwent transthoracic echocardiography and multidetector comput-
erized tomography before and after valve implantation. Clinical and echocardiographic follow
up was obtained at 30 days and for the initial 10 patients after one year. Outcomes were
reported according to the Valve Academic Research Consortium guidelines.
Results: All 15 device implants were successful. Aortic valve area increased from 0.7
0.1 cm2 to 1.6  0.4 cm2 post procedure (p  0.01) and 1.8  0.3 cm2 at one-year
follow-up. Mean trans-aortic gradient decreased from 36.3  14.2 mmHg to 10.6  5.4
mmHg post-procedure (p  0.001) and to 10.8  4.1 mmHg at one year follow-up. All
patients were in NYHA class I (25%) or II (75%) at one-year follow-up and only one
patient had more than mild paravalvular regurgitation at one-year follow-up. Four patients
(27%) received a new permanent pacemaker. Survival was 87% at 30 days and 80% at
one year. None of the deaths were valve related.
Conclusions: Transcatheter aortic valve replacement with the CENTERA transcatheter
heart valve and motorized delivery system is feasible and leads to excellent short- and
mid-term clinical and hemodynamic outcomes.
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Outcome after a TAVI procedure with self expanding bioprothesis using
Corevalve or Accutrack delivery device: France 2 Registry results
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Delphine Hayat1, Jean Luc Monin1, Alain Prat2, Marc Laskar3, Martine Gilard4,
Emmanuel Teiger1
1Henri Mondor University Hospital, Creteil, France, 2University Hospital of Lille,
Cardiological hospital, Lille Cedex, France, 3University Hospital of Limoges,
hôpital dupuytren, Limoges, France, 4La Cavale Blanche Hospital, Brest, France
Background: Permanent pacemaker Implantation (PP) following high degree atrio-
ventricular block is a frequent complication after Transcatheter Aortic Valve Implantation
(TAVI) by using self expanding bioprothesis (SEB) system. Recent improvements of SEB
from CoreValve Device (CD) to Accutrack CoreValve Device (ACD) have aimed to
allow easier delivery and also expected to reduce the PP rate. However, the clinical
outcome of PP occurrence and differences of PP rate between MCD and ACD after TAVI
remains unclear.
Methods: A total of 958 patients (82	7 years; female: 49%) with severe symptomatic
aortic stenosis were selected SEB between January 2010 and October 2011 in 33 centers
of the FRANCE 2 Registry. The current study investigated 1) the incidence of PP rate
according to the differences of 2 devices and 2) the midterm clinical outcome of PP
occurrence after TAVI.
Results: Procedural success rate was 96.9% and PP rate was 22.4% in overall population.
CD and ACD were implanted in 54.5% (n522) and 41.5% (n436) of patients,
respectively. There was no significant differences of PP rate between CD and ACD
(21.6% vs. 23.4%, p0.52). During the mean follow-up of 242	179 days, the PP
occurrence was not associated with increasing all cause mortality when compared with
non PP occurrence 14.4 % Vs 13.2 % (p0.33).
Conclusions: PP remains frequent after TAVI with SEB and device improvement failed
to show an impact on PP implantation rate. Overall mortality was not impacted by PP.
TCT-802
Impact of experience on TAVI outcome a propensity matched analysis from
the PRAGMATIC Plus Initiative
Nicolas Van Mieghem1
1Erasmus MC, Rotterdam, Netherlands
Background: Not much is known about the impact of the mounting clinical experience
and technological refinements on clinical endpoints after TAVI.
Methods: We retrospectively analyzed 793 consecutive TF-TAVI patients from 4
European centers and evaluated experience in three propensity score matched cohorts
subcategorized based on enrollment date.
Results: Three propensity score matched cohorts of 214 TF-TAVI patients were
identified. With mounting experience and moving from the initial to the last cohort,
all-cause 30-day mortality trended to be lower (7.0% in T1 vs. 3.7% in T3, p 0.16) but
with improved 1-year survival (79% vs. 86%, p  0.016). Over time there were
significantly less major vascular complications (15% vs. 7.9%, p  0.023), life
threatening (17.8% vs. 7.9%, p 0.003) and major bleedings (22.4% vs. 12.1%, p 
0.007). Major vascular complications and life-threatening bleedings due to closure device
failure decreased significantly (9.2% vs. 3.1%, p  0.01 and 5.7% vs. 1 %, p  0.01
respectively).The combined safety endpoint dropped from 31.3% in T1 to 17.8% in T3
(p  0.001). By multivariable analysis (including adjustment for arterial sheath size) the
last cohort as compared to the initial cohort was associated with significant reductions in
30-day mortality (OR 0.35, 95% CI 0.12 – 0.96), stage 3 AKI (OR 0.12, 95% CI 0.29 –
0.93) and the combined safety endpoint (OR 0.52, 95% CI 0.29 – 0.93).
Conclusions: Growing TAVI experience results in significant reductions in major
vascular complications, life threatening bleedings and the combined clinical safety
endpoint and improved 1-year survival.
TCT-803
Emergency and prophylactic use of miniaturized veno-arterial extracorporeal
membrane oxygenation (vaECMO) in transcatheter aortic valve implantation
(TAVI)
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Alois Philipp1, Günter Riegger1, Christof Schmid1
1University of Regensburg Medical Center, Regensburg, Bavaria
Background: In transcatheter aortic valve implantation (TAVI), short term mortality
closely relates to life threatening procedural complications. Veno-arterial extracorporeal
membrane oxygenation (vaECMO) can be used to stabilize the patient in emergency
situations. However, for the prophylactic use of ECMO in very high risk patients
undergoing TAVI there is no experience. We report our center’s experience using
vaECMO in TAVI.
Methods: From January 2009 to August 2011, we performed 131 TAVI. Emergency
vaECMO was required in 8 cases (7%): ventricular perforation (n3), hemodynamic
instability/ cardiogenic shock (n4), hemodynamic deterioration due to ventricular
tachycardia (n1). From August 2011 on, during 83 procedures, prophylactic vaECMO
was systematically used in very high risk patients (n9, 11%) and emergency vaECMO
in one case (1%) due to ventricular perforation.
Results: Median logistic EuroScore in prophylactic vaECMO patients was considerably
higher compared to the remaining TAVI population (30% vs. 15%, p0.0003) while
logistic EuroScore of patients with emergency vaECMO was comparable (18% vs. 15%,
p0.08). Comparing prophylactic to emergency vaECMO, procedural success, proce-
dural related death, and 30-day mortality were 78% vs. 100% (p0.5), 33% vs. 0%
(p0.2) and 44% vs. 0% (p0.08), respectively. Major vascular complications and rate
of life threatening bleeding did not differ in both groups (11% vs. 11%, p0.99 and 11%
vs. 33%, p0.6) and were not vaECMO related.
Conclusions: Life-threatening complications during TAVI can be managed using
emergency vaECMO but mortality remains high. Systematic use of prophylactic
vaECMO in very high risk patients is safe and might be advocated in selected high risk
patients.
TCT-804
Safety and Efficacy of 14Fr Balloon Expandable Sheath for Trans-catheter
Aortic Valve Implantation (TAVI)
Hirotsugu Mitsuhashi1, Stephen Fremes2, Dennis Ko2, Sam Radhakrishnan2,
Rafael Wolff2
1St Lukes International Hospital, Tokyo, Tokyo, 2Sunnybrook Health Science
Centre, Toronto, Ontario
Background: The aim of this study is to show access site complication and success rate
in trans-catheter aortic valve implantation (TAVI) with 14Fr balloon expandable sheath
which is expanded to 19Fr in artery by comparing to those with standard 18Fr sheath.
Methods: From 106 consecutive patients who underwent TAVI, patients who had
subclavian (n  4) or trans direct aortic access (n  2) were excluded. Remaining 100
patients who underwent TAVI through femoral access were included in the study. Whole
sample was divided into 2 groups: standard18Fr (n  82) and 14Fr (n  18) balloon
expandable sheath group. Successful TAVI was defined as optimal positioning of a stent
valve with hemodynamical stability without additional valve. Access site complication
was defined as bleeding/hematoma which needed blood transfusion and vascular injury
including dissection, perforation, AV fistula and pseudoanuerysm which needed un-
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planned surgery or intervention. Difference of success and access site complication rate
was tested with chi square test. OR and its 95% CI were calculated with multivariate
logistic regression analysis adjusted by patient background.
Results: 16 (19.5%) and 2 (11.1%) patients had access site complications in 18Fr and
14Fr group, respectively. No significant difference was obtained (p  0.52). 73 (89.0%)
and 18 (100%) patients had successful TAVI in 18Fr and 14Fr group, respectively. No
statistical difference was observed in success rate as well (p  0.36). Although 14 Fr
group showed shorter fluoroscopic time, it was not significant (26.4 vs 27.2 min, p 
0.77). There was no difference in contrast amount (133.8 vs 141.4ml, p 0.67). Adjusted
OR of access site complication in 14 Fr compared to 18Fr was 0.20 (95%CI: 0.03-1.59,
p 0.12). OR of successful TAVI was not calculative since no failed case was observed
in 14Fr group.
Conclusions: Compared with standard 18Fr sheath, 14Fr balloon expandable sheath
showed lower complication rate, higher success rate, shorter fluoroscopic time and smaller
amount of contrast use but they did not reach statistical significance. Further investigation
should be needed.
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Impact of Pulmonary Hypertension on Outcome after Transcatheter Aortic
Valve Implantation
Alexander Lauten1, Ralf Zahn2, Axel Linke3, Sack Stefan4, Markus Ferrari1,
Horst Sievert5, Eberhard Grube6, Ulrich Gerckens7, Jochen Senges8,
Hans Figulla1
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5CardioVascular Center Frankfurt, Frankfurt, Germany, 6University Hospital
Bonn, Bonn, Bonn, 7Hospital St Petrus, Heart center Rhein-Ahr, Bonn, Germany,
8Institut fuer Herzinfarktforschung, Essen, Germany
Background: Pulmonary Hypertension (PH) is considered a significant risk factor in
patients with aortic valve disease for and the prognostic implicationions of PH are unclear
in high-risk patients undergoing Transcatheter Aortic Valve Implantation (TAVI).
Therefore, we sought to assessed the impact of preoperative PH on outcome in patients
undergoing TAVI.
Methods: Between January 2009 and June 2010, a total of 1285 patients undergoing
TAVI were included in this registry (mean age 81.76.1, 41.9% males). Patients were
grouped according to systolic pulmonary artery pressure (PASP): group I, 277 patients,
(21.6%) with PASP30mmHg, group II, 598 patients (46.5%) with PASP 30-50 mmHg
and group III, 410 patients (31.9%) PASP 50mmHg. Patients in group III had a
significantly higher Euroscore (2616mmHG vs. group I 1811mmHg vs. group II
1811mmHg; p0.0001) and were more symptomatic with a higher proportion
presenting in NYHA class IV (28.5% vs. group I 13.6% vs. group II 8.3%; p0.0001).
Results: In all subgroups, the majority of procedures was performed transfemorally with
a high procedural success rate. The rate of TAVI-associated complications was compa-
rable independent of PASP (cerebrovascular accident: group I 3.3% vs. group II 3.9 % vs.
group III 2.0%, p0.25; permanent pacemaker: group I 33.8% vs. group II 38.1 % vs.
group III 35.2%, p0.24). Functional NYHA class and survival at 30 days demonstrated
excellent outcome in all subgroups (30-day survival group I: 91.2% vs. group II 93.0% vs.
group III 91.9%; p0.59). All subgroups experienced a significant improvement of
self-assessed quality-of-life (according to EuroQol5d-visual analogue scale) with the
largest gain in group III (0.1120.35 vs. group I 0.0550.32 vs. group II 0.040.32;
p0.15).
Conclusions: In conclusion, non-surgical patients severe AS have a high prevalence of
PH. However, based on the registry data, early mortality after TAVI is not increased in
patients with PH. This subgroup benefit from the procedure with functional improvement
and improved postoperative quality-of-life.
TCT-806
Long-Term Outcomes From The CoreValve Transcatheter Aortic Valve
Australia-New Zealand Study
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David Muller9
1Monash University, Melbourne, Australia, 2Alfred Hospital, Melbourne, Victoria,
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Background: Percutaneous transcatheter aortic valve implantation (TAVI) is a proven
therapy for patients at high risk for surgical AV replacement. Although numerous studies
have reported the safety and efficacy of TAVI, integration of this therapy into standard of
care varies widely by country, and country-or region-specific data could support local
adoption and approval. The CoreValve Australia-New Zealand Study (ANZ) is evaluating
the safety and effectiveness of the CoreValve System (Medtronic, Minneapolis, MN) in an
Australia-New Zealand patient population.
Methods: ANZ is a prospective, multicenter, single-arm, study enrolling patients with
severe symptomatic AS from 10 experienced centers. Primary safety endpoints were;
cardiac death (CD) and major adverse cardiovascular/ cerebrovascular events (MACCE;
all-cause death, myocardial infarction [MI], stroke, or reintervention) at 30 days. All
clinical source documentation will be fully monitored. An independent Clinical Events
Committee adjudicated MACCE events and death based on VARC.
Results: Baseline characteristics (n428) include: 45% women, age 83.95.9 y; 76.7%
NYHA Class III/IV, STS 5.94.2, logEuroSCORE 17.611.0, 35.3% atrial fibrillation,
31.3% prior PCI, 25.7%,previous CABG; 20.1% prior MI, and prior balloon valvulo-
plasty in 22.7%. Procedural success was 98.4%.Vascular complications, major 4.0%;
bleeding, life- threatening/disabling 4.7%, major 8.9%. At 30 days, 97.9% of patients
were free from CD, 96.4% from stroke, and 85.8% from MACCE. 79.8% improved 1
NYHA class. AV area significantly improved by 1.20.5 cm2 and mean gradient by
41.716.7 mmHg; 81.6% of patients had  mild AR. At 1 year, 93.5% were free from
CD, 94.7% from stroke and 78.0% from MACCE. NYHA, AR, AV area and mean
gradient improvements persisted at 1 year. PPM rates were evaluated by experience; for
30 implants, the PPM rate was 33.1%; for 30 implants; 19.9%. No valve migrations
have been reported.
Conclusions: Early to midterm outcomes showed mortality and morbidity outcomes
within expectations for percutaneously treated patients with severe symptomatic AS in
this very high-risk subgroup. Longer term follow-up will be presented at the time of the
meeting.
TCT-807
Self-expandable Transcatheter Aortic Valve Implantation for Aortic Stenosis
after Mitral Valve Surgery
Giuseppe Bruschi1, Federico De Marco1, Alberto Barosi1, Luca Botta1,
Paola Colombo1, Jacopo Oreglia1, Sandra Nonini1, Luigi Martinelli1,
Silvio Klugmann1
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Background: Transcatheter aortic valve implantation (TAVI) has emerged as a valuable
option to treat patients with symptomatic severe aortic stenosis not being considered for
surgery because of significant comorbidities. Concerns exist about treating patients who
previously underwent mitral valve surgery for possible interference between the percu-
taneous aortic valve and the mitral prosthesis or ring.
Methods: At our Center from May 2008 one hundred sixty-one patients (74 male) with
severe symptomatic aortic stenosis, mean age 819 years, were eligible for TAVI. Nine
patients affected by severe aortic stenosis, previously underwent mitral valve surgery (4
mono-leaflet, 3 bi-leaflet, 1 bioprosthesis, 1 mitral ring); they were judged high risk
surgical candidates, after combined cardiac surgeons and cardiologist evaluation, and
underwent TAVI (Table I).
Results: Seven patients underwent standard femoral retrograde CoreValve implantation,
two patient underwent a direct aortic implantation through a mini-thoracotomy. All
patients experience immediate improvement of the hemodynamic status. No deformation
of the nitinol tubing of the CoreValve neither distortion or malfunction of the mechanical
valve or mitral ring occurred as assessed by echographic and fluoroscopic evaluation. No
major post-operative complications occurred. In all patients echocardiography evidenced
normal valve function during follow-up.
Patient characteristics and results
Nr % or SD
Gender (female) 7 77.7%
Mean Age (years) 73.7 6.6
Left Ventricle Ejection Fraction (%) 34 12
Mean Aoric Gradient (mmHg) 48 14
Mean STS Score Mortality (%) 13.3 10.5
PM Implant 0 –
Stroke 0 –
30-day Mortality 0 –
Conclusions: Our experience confirms the safety and feasibility of CoreValve implan-
tation in patients with mechanical / biological mitral valves or mitral annuloplasty ring.
TCT-808
Expansion Geometry of the Edwards Sapien XT aortic valve following a
MSCT guided oversizing approach
Alexander Leber1, Uli Ebersberger2, Ellen Hoffmann3, Markus Kasel4
1Sunnybrook Helth Science Centre, Toronto, Ontario, 2Heart Centre, Munich
Bogenhausen, Munich, BY, 3Heart Centre Munich Bogenhausen, Munich, by,
4German Heart Centre, Munich, Germany
Background: So far device sizing before TAVI is recommended by Echo measurements
which are however known to be somehow inaccurate taking into acount the oval shape of
the anulus and device undersizing is a major cause for paravalvular regurgitation. In the
current study we therefore assessed the post implantation expansion pattern and the
functional performance of the Edwards Sapien XT (Edwards Lifesciences, California)
device after TAVI and a MSCT guided sizing approach.
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